Item 5.07 Submission of Matters to a Vote of Security Holders

Forma Therapeutics Holdings, Inc. (the "Company") held its Annual Meeting of Stockholders on June 8, 2022 (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders considered and voted on the four proposals set forth below, each of which is described in greater detail in the Company's Proxy Statement, filed with the Securities and Exchange Commission on April 27, 2022. The final voting results are set forth below.

Proposal 1 - Election of Class II Director Nominees

The stockholders of the Company elected Peter Wirth, J.D. and Timothy P. Clackson, Ph.D. as Class II directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2025 and until their successors have been duly elected and qualified or until their earlier death, resignation or removal. The results of the stockholders' vote with respect to the election of the Class II directors were as follows:



                                Votes            Votes          Broker
Name                             For           Withheld        Non-Votes
Peter Wirth, J.D.              29,703,376       3,905,968       2,026,775
Timothy P. Clackson, Ph.D.     27,051,786       6,557,558       2,026,775

Proposal 2 - Ratification of Appointment of the Company's Independent Registered Public Accounting Firm

The stockholders of the Company ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022. The results of the stockholders' vote with respect to such ratification were as follows:



  Votes       Votes
   For       Against   Abstain   Broker Non-Votes
35,633,955    2,161       3            N/A

Proposal 3 - Non-binding Advisory Vote on the Compensation of Named Executive Officers

The stockholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. The results of the stockholders' vote with respect to the compensation of the named executive officers were as follows:



  Votes       Votes
   For       Against   Abstain   Broker Non-Votes
32,661,443   931,372   16,529       2,026,775

Proposal 4 - Non-binding Advisory Vote on the Preferred Frequency of Future Votes on Compensation of Named Executive Officers

The stockholders of the Company approved, on a non-binding, advisory basis, to set the frequency of future non-binding advisory votes on the compensation of the Company's named executive officers to every one year. The results of such vote were as follows:



   One        Two     Three
   Year      Years    Years    Abstain   Broker Non-Votes
33,150,699   2,115   117,304   339,226      2,026,775

In light of such vote, the Company's Board of Directors has determined that the Company will hold future non-binding advisory votes on executive compensation on an annual basis until the next required vote on the frequency of stockholder votes on the compensation of the named executive officers.

No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.


                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses